Identification of RCAN1's Role in Hepatocellular Carcinoma Using Single-cell Analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Aug 27

PMID 39192218

Authors

Ziqi Yang

Xiwei Deng

Didi Wen

Lijun Sun

Rui An

Jian Xu

Affiliations

Soon will be listed here.

Abstract

Background: The regulator of calcineurin 1 (RCAN1) is expressed in multiple organs, including the heart, liver, brain, and kidney, and is closely linked to the pathogenesis of cardiovascular diseases, Down syndrome, and Alzheimer's disease. It is also implicated in the development of various organ tumors; however, its potential role in hepatocellular carcinoma (HCC) remains poorly understood. Therefore, the objective of this study was to investigate the potential mechanisms of RCAN1 in HCC through bioinformatics analysis.

Methods: We conducted a joint analysis based on the NCBI and TCGA databases, integrating both bulk transcriptome and single-cell analyses to examine the principal biological functions of RCAN1 in HCC, as well as its roles related to phenotype, metabolism, and cell communication. Subsequently, an RCAN1-overexpressing cell line was established, and the effects of RCAN1 on tumor cells were validated through in vitro experiments. Moreover, we endeavored to identify potential related drugs using molecular docking and molecular dynamics simulations.

Results: The expression of RCAN1 was found to be downregulated in 19 types of cancer tissues and upregulated in 11 types of cancer tissues. Higher levels of RCAN1 expression were associated with improved patient survival. RCAN1 was predominantly expressed in hepatocytes, macrophages, endothelial cells, and monocytes, and its high expression not only closely correlated with the distribution of cells related to the HCC phenotype but also with the distribution of HCC cells themselves. Additionally, Rcan1 may directly or indirectly participate in metabolic pathways such as alanine, aspartate, and glutamate metabolism, as well as butanoate metabolism, thereby influencing tumor cell proliferation and migration. In vitro experiments confirmed that RCAN1 overexpression promoted apoptosis while inhibiting proliferation and invasion of HCC cells. Through molecular docking of 1615 drugs, we screened brompheniramine as a potential target drug and verified our results by molecular dynamics.

Conclusion: In this study, we revealed the relationship between RCAN1 and HCC through bioinformatics methods, verified that RCAN1 can affect the progress of the disease through experiments, and finally identified potential therapeutic drugs through drug molecular docking and molecular dynamics.

References

Baek K, Zaslavsky A, Lynch R, Britt C, Okada Y, Siarey R . Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009; 459(7250):1126-30. PMC: 2724004. DOI: 10.1038/nature08062. View

Wang C, Wang Y, Hong T, Ye J, Chu C, Zuo L . Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma. Cell Death Differ. 2020; 28(3):932-951. PMC: 7937678. DOI: 10.1038/s41418-020-00626-6. View

Kyrylkova K, Kyryachenko S, Leid M, Kioussi C . Detection of apoptosis by TUNEL assay. Methods Mol Biol. 2012; 887:41-7. DOI: 10.1007/978-1-61779-860-3_5. View

Mitchell A, Jayakumar L, Koleilat I, Qian J, Sheehan C, Bhoiwala D . Brain expression of the calcineurin inhibitor RCAN1 (Adapt78). Arch Biochem Biophys. 2007; 467(2):185-92. DOI: 10.1016/j.abb.2007.08.030. View

Porter A, Janicke R . Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6(2):99-104. DOI: 10.1038/sj.cdd.4400476. View

Song Z, Cao Q, Ruan H, Yang H, Wang K, Bao L . RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. Exp Cell Res. 2018; 372(2):118-128. DOI: 10.1016/j.yexcr.2018.09.017. View

Liu C, Zheng L, Wang H, Ran X, Liu H, Sun X . The RCAN1 inhibits NF-κB and suppresses lymphoma growth in mice. Cell Death Dis. 2015; 6:e1929. PMC: 4632290. DOI: 10.1038/cddis.2015.260. View

Singal A, El-Serag H . Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015; 13(12):2140-51. PMC: 4618036. DOI: 10.1016/j.cgh.2015.08.014. View

Fritz I, Wagner P, Olsson H . Improved survival in several cancers with use of H-antihistamines desloratadine and loratadine. Transl Oncol. 2021; 14(4):101029. PMC: 7868613. DOI: 10.1016/j.tranon.2021.101029. View

10.

Gao R, Bai S, Henderson Y, Lin Y, Schalck A, Yan Y . Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021; 39(5):599-608. PMC: 8122019. DOI: 10.1038/s41587-020-00795-2. View

11.

Chidambaranathan-Reghupaty S, Fisher P, Sarkar D . Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021; 149:1-61. PMC: 8796122. DOI: 10.1016/bs.acr.2020.10.001. View

12.

Wang S, Wang Y, Qiu K, Zhu J, Wu Y . RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target. Mol Med. 2020; 26(1):118. PMC: 7709393. DOI: 10.1186/s10020-020-00249-0. View

13.

Gagliani N, Hu B, Huber S, Elinav E, Flavell R . The fire within: microbes inflame tumors. Cell. 2014; 157(4):776-83. DOI: 10.1016/j.cell.2014.03.006. View

14.

Petroni G, Buque A, Coussens L, Galluzzi L . Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov. 2022; 21(6):440-462. DOI: 10.1038/s41573-022-00415-5. View

15.

van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark A, Berendsen H . GROMACS: fast, flexible, and free. J Comput Chem. 2005; 26(16):1701-18. DOI: 10.1002/jcc.20291. View

16.

Wong H, Buck J, Borski C, Pafford J, Keller B, Milstead R . RCAN1 knockout and overexpression recapitulate an ensemble of rest-activity and circadian disruptions characteristic of Down syndrome, Alzheimer's disease, and normative aging. J Neurodev Disord. 2022; 14(1):33. PMC: 9128232. DOI: 10.1186/s11689-022-09444-y. View

17.

Rusnak F, Mertz P . Calcineurin: form and function. Physiol Rev. 2000; 80(4):1483-521. DOI: 10.1152/physrev.2000.80.4.1483. View

18.

Chen F, Shi Q, Pei F, Vogt A, Porritt R, Garcia Jr G . A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol Syst Biol. 2021; 17(8):e10239. PMC: 8328275. DOI: 10.15252/msb.202110239. View

19.

Zheng J, Wu D, Wang L, Qu F, Cheng D, Liu X . mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1. Gastroenterol Res Pract. 2021; 2021:6691305. PMC: 8075694. DOI: 10.1155/2021/6691305. View

20.

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View